7/29/2015 | BKCVHY | S&P upgrades Salix
|
4/6/2015 | CAHYLM | Salix Pharmaceuticals sets redemption price for $262 million 6% notes
|
4/1/2015 | CVLM | Salix convertible noteholders get change-of-control put option
|
4/1/2015 | CAHYLM | Valeant to redeem Salix’s 6% senior notes due 2021 in two stages
|
3/19/2015 | HY | Market Commentary: Rite Aid, Sensata price deals; new Rite Aid rises; Guitar Center gains; funds lose $1 billion
|
3/16/2015 | PP | Market Commentary: Salix convertibles add on sweetened Valeant deal; Amarin extends gains; Actavis in action
|
3/16/2015 | CV | Market Commentary: Salix convertibles add on sweetened Valeant deal; Amarin extends gains; Actavis in action
|
3/16/2015 | CV | Market Commentary: Morning Commentary: Salix trades actively on sweetened Valeant deal; SanDisk, Tesla in action
|
3/12/2015 | HY | Market Commentary: United Rentals, CenturyLink, Reliance deals price; Valeant upsizes; funds lose $1.96 billion
|
3/12/2015 | BKCVDDEMIGPV | Market Commentary: United Rentals two-parter, CenturyLink price; Valeant upsizes; funds lose $1.96 billion
|
3/11/2015 | HY | Market Commentary: Shea Homes two-parter, Surgical Care, GFL deals price; Valeant up on Endo bid for Salix
|
3/11/2015 | BKCVDDEMIGPV | Market Commentary: Shea Homes two-parter, Surgical Care, GFL deals price; Valeant up on Endo bid for Salix
|
3/9/2015 | HY | Market Commentary: Crestwood, Masonite, HealthSouth drive by; calendar builds massively; Whiting jumps on sale talk
|
2/25/2015 | CVLM | Salix notifies 2.75% convertible holders of expected make-whole change
|
2/24/2015 | HY | Market Commentary: Digicel drives by, moves up; recent bonds busy; Sitel bonds gain as Onex eyes possible sale
|
2/24/2015 | BKCVDDEMIGPV | Market Commentary: Digicel drives by, moves up; recent bonds busy; Sitel bonds gain as Onex eyes possible sale
|
2/23/2015 | HY | Market Commentary: DISH weakens after numbers, CEO retirement; Salix gains on Valeant merger; Toys’ bonds push up
|
2/23/2015 | BKCVDDEMIGPV | Market Commentary: DISH weakens after numbers, CEO retirement; Salix gains on Valeant merger; Toys’ bonds up
|
2/23/2015 | PP | Market Commentary: Salix flat to lower in active trade after merger news; Spectrum sinks on patent ruling
|
2/23/2015 | CV | Market Commentary: Salix flat to lower in active trade after merger news; Spectrum sinks on patent ruling
|
2/23/2015 | BKCVHY | Moody’s could raise Salix
|
2/23/2015 | CV | Market Commentary: Morning Commentary: Salix trades actively, lower on merger news; Spectrum sinks on patent ruling
|
2/3/2015 | PP | Market Commentary: Isis adds on hedge after drug data disappoints; LinkedIn adds outright, on hedge
|
2/3/2015 | CV | Market Commentary: Isis adds on hedge after drug data disappoints; LinkedIn adds outright, on hedge
|
12/10/2014 | SP | New Issue: Barclays prices $1.71 million 8.6% airbag autocallables linked to Salix
|
12/4/2014 | PP | Market Commentary: NXP Semiconductors extends gains; energy sector heavy; ANI Pharmaceuticals on tap
|
12/4/2014 | CV | Market Commentary: NXP Semiconductors extends gains; energy sector heavy; ANI Pharmaceuticals on tap
|
12/3/2014 | SP | Barclays plans 7%-9% airbag autocallables on Salix Pharmaceuticals
|
11/10/2014 | PP | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Market Commentary: Morning Commentary: Dendreon drops after bankruptcy filing; Salix Pharmaceuticals bounces slightly
|
11/7/2014 | BK | Market Commentary: Salix slides with onslaught of negative news; Southeast PowerGen, Essar Steel, US LBM break
|
11/7/2014 | CLHY | Market Commentary: Salix slides with onslaught of negative news; Southeast PowerGen, Essar, US LBM break
|
11/7/2014 | PP | Market Commentary: Salix Pharmaceuticals slumps outright, adds on heavy deltas; Allcripts Healthcare drops
|
11/7/2014 | CV | Market Commentary: Salix Pharmaceuticals slumps outright, adds on heavy deltas; Allcripts Healthcare drops
|
11/7/2014 | BKCVHY | Moody’s reviews Salix
|
11/7/2014 | BKCVHY | S&P lowers Salix, debt
|
11/7/2014 | CV | Market Commentary: Morning Commentary: Salix slumps on earnings miss, lowered guidance; AllScripts Healthcare drops
|
11/6/2014 | DD | Market Commentary: Molycorp bonds mauled on poor earnings; Cliffs also clobbered; hard-hit Aegerion comes back
|
11/6/2014 | HY | Market Commentary: Molycorp bonds mauled on poor earnings; Cliffs clobbered too; hard-hit Aegerion comes back
|
11/6/2014 | PP | Market Commentary: LinkedIn gains after pricing at cheap end; Aegerion regains ground; Salix shares plunge
|
11/6/2014 | CV | Market Commentary: LinkedIn gains after pricing at cheap end; Aegerion regains ground; Salix shares plunge
|
10/28/2014 | SP | New Issue: UBS prices $447,000 contingent absolute return autocallables on Salix
|
10/22/2014 | SP | UBS plans contingent absolute return autocallables linked to Salix
|
10/3/2014 | PP | Market Commentary: Downsized Starwood edges up from discount; Salix flat to lower; Red Hat extends gains
|
10/3/2014 | CV | Market Commentary: Downsized Starwood edges up from discount; Salix flat to lower; Red Hat extends gains
|
10/3/2014 | CV | Market Commentary: Morning Commentary: Downsized Starwood rises from discount; Salix flat to lower; Red Hat up
|
9/23/2014 | PP | Market Commentary: Tesaro looks rich at the mids; Salix up in line or better amid M&A talk; SolarCity on tap
|
9/23/2014 | CV | Market Commentary: Tesaro looks rich at the mids; Salix up in line or better amid M&A talk; SolarCity on tap
|
9/23/2014 | CV | Market Commentary: Morning Commentary: Planned Tesaro looks rich on the mids; Salix active amid more M&A chatter
|
8/27/2014 | CV | Market Commentary: Aegerion adds on swap with higher shares; Titan Machinery slips on swap on lower shares
|
8/19/2014 | PP | Market Commentary: Salix surges on takeout rumors; Illumina paper trades actively; PDL BioPharma in line
|
8/19/2014 | CV | Market Commentary: Salix surges on takeout rumors; Illumina paper trades actively; PDL BioPharma in line
|
7/23/2014 | SP | New Issue: Citi sells $646,000 contingent absolute return autocallables on Salix Pharmaceuticals
|
7/9/2014 | PP | Market Commentary: Market quiet as focus shifts to earnings; Accuray sees outright interest; Salix in line
|
7/9/2014 | CV | Market Commentary: Market quiet as focus shifts to earnings; Accuray sees outright interest; Salix in line
|
7/1/2014 | PP | Market Commentary: New Starwood Waypoint adds; Salix jumps outright, flat on hedge; Tower active; Ctrip eyed
|
7/1/2014 | CV | Market Commentary: New Starwood Waypoint adds; Salix jumps outright, flat on hedge; Tower active; Ctrip eyed
|
7/1/2014 | CV | Market Commentary: Morning Commentary: Upsized Starwood Waypoint adds on debut; Salix jumps outright, flat on hedge
|
2/18/2014 | CV | Market Commentary: Convertibles thinly traded to start week; Ctrip.com paper higher in line; Chemed expands
|
1/13/2014 | CV | Market Commentary: Goldcorp acquisition spurs Detour Gold, other miners; EnPro jumps outright; Tower weaker
|
1/2/2014 | BK | Market Commentary: IMS Health unchanged on IPO news; JLL/Delta sets timing; Dixie, PSAV, SeaStar ready deals
|
12/17/2013 | BK | Market Commentary: Salix, Las Vegas, Infor, Four Seasons, RedPrairie, Hillman, Edmentum, Sensus, GCA break
|
12/12/2013 | HY | New Issue: Salix prices $750 million seven-year notes at par to yield 6%
|
12/12/2013 | HY | Market Commentary: Salix, Walter, Arch lead $2.44 billion session; existing Arch bonds up; funds gain $16 million
|
12/11/2013 | HY | Salix Pharmaceuticals talks $750 million seven-year notes to yield 6%-61/4%; pricing Thursday
|
12/11/2013 | HY | Market Commentary: Endo, Digicel, Ashtead drive-bys dominate $1.9 billion primary session; new Sprint hanging in
|
12/6/2013 | HY | Market Commentary: Upsized Ultra Petroleum, Abengoa deals pace busy session, cap $10.5 billion week
|
12/6/2013 | HY | Salix Pharmaceuticals sets Monday roadshow start for $750 million seven-year notes via Jefferies
|
12/5/2013 | BK | Market Commentary: Nexstar breaks; Samson, Hillman slip on repricings; Salix, Altisource revisions surface
|
12/5/2013 | BK | Salix cuts spread on $1.2 billion term loan B to Libor plus 325 bps
|
12/3/2013 | BK | Market Commentary: RCN breaks; Bluestem tweaks deal; price talk emerges on multiple deals with launches
|
12/3/2013 | BK | Salix launches $1.2 billion term loan B at Libor plus 350-375 bps
|
12/3/2013 | HY | Salix expected to start roadshow on Monday for $750 million senior notes via Jefferies
|
12/2/2013 | BKCVHY | Moody's rates Salix loans Ba1, notes B2
|
12/2/2013 | BKCVHY | S&P assigns BB to Salix loan, gives B to notes
|
11/26/2013 | BK | Market Commentary: Around 20 deals break into busy pre-holiday secondary market; Dayco, Nexstar updates surface
|
11/26/2013 | BK | Salix Pharmaceuticals to launch $1.35 billion facility on Dec. 3
|
11/18/2013 | BKHY | Salix plans $1.35 billion credit facility, $750 million notes
|
11/8/2013 | BKHY | Salix plans $1.95 billion of new financing, $150 million revolver
|
6/10/2013 | CV | Market Commentary: Convertibles quiet, weaker; Ryland under pressure; Cornerstone OnDemand, Workday on tap
|
5/13/2013 | CV | Market Commentary: Endo Health 'comes in' on FDA news; Theravance still trades mixed; Shutterfly on deck
|
5/10/2013 | CV | Market Commentary: Theravance mixed on COPD drug approval; Meritor improves; Electronic Arts extends gains
|
4/16/2013 | CV | Market Commentary: NetApp active, in line with shares; Intel trades ahead of earnings; Chemed flat to higher
|
5/8/2012 | CV | Market Commentary: Thompson Creek slides; Annaly on tap; Dendreon drops outright, on hedge; Salix seen flat
|
3/26/2012 | CV | Market Commentary: Investment-grade issues dominate convertibles market; Medtronic higher; MF Global dips
|
3/16/2012 | CV | Market Commentary: Convertibles slightly weaker; Salix lower; Alliant Techsystems adds on hedge; DryShips up
|
3/16/2012 | CV | Salix greenshoe exercised; 1.5% convertibles lifted to $690 million
|
3/15/2012 | CV | Market Commentary: Medivation treads water; Salix comes in on hedge since issue; Clearwire flat; Southwest adds
|
3/13/2012 | CV | New Issue: Salix prices upsized $600 million seven-year convertibles to yield 1.5%, up 35%
|
3/13/2012 | CV | Market Commentary: New Salix pops, then retreats on debut; Medivation talk revised; Wintrust notes to price
|
3/12/2012 | CV | Market Commentary: Salix Pharmaceuticals, Medivation to price; Suntech Power slips; Central European extends gains
|
3/12/2012 | CV | Salix talks $500 million seven-year convertibles at 1.5%-1.75%, up 35%
|
11/9/2011 | CV | Market Commentary: Rovi gains dollar neutral as dour outlook torpedoes stock; Salix adds outright; GM lower
|
2/24/2011 | CV | Market Commentary: Salix lower on hedge on drug setback; Newmont Mining drops in line after earnings released
|
6/3/2010 | CV | Salix greenshoe exercise lifts 2.75% convertibles to $345 million
|
5/28/2010 | CV | New Issue: Salix details upsized $300 million five-year convertibles, priced to yield 2.75%, up 30%
|
5/28/2010 | CV | Market Commentary: Transocean slips with sector; Salix gains on debut; tough month for convertibles trading
|
5/27/2010 | CV | New Issue: Salix prices upsized $300 million five-year convertibles to yield 2.75%, up 30%
|
5/27/2010 | CV | Market Commentary: Transocean rises, then pares gains; SunPower, NetApp up; Salix sells upsized $300 million
|
11/17/2009 | CV | Salix Pharmaceuticals files automatic shelf for stock and preferreds
|
11/14/2008 | SS | Baker Bros. Investments increases stake to 9.7% in Salix
|
8/22/2008 | CV | Salix greenshoe fully exercised, lifts 5.5% 20-year convertibles to $60 million
|
8/18/2008 | CV | New Issue: Salix prices upsized $55 million 20-year convertibles to yield 5.5%, up 20%
|
8/18/2008 | CV | Market Commentary: Fannie Mae, Huntington edge lower; Amylin expands as shares sink; Cheniere places private deal
|
11/7/2006 | BT | Salix quarterly product revenues of $51.2 million driven by Xifaxan, Colazal
|
9/5/2006 | BT | Salix, Debiopharm sign Sanvar license agreement
|
8/28/2006 | BT | Salix granted pediatric exclusivity for Colazal anti-inflammatory
|
8/2/2006 | BT | Salix's MoviPrep gets FDA marketing approval
|
7/5/2006 | BT | Salix, Cedars-Sinai sign license agreement
|
6/29/2006 | BT | Salix says it can double '05 revenues within 4 years
|
6/21/2006 | BT | FDA sets Aug. 2 PDUFA date for Salix's MoviPrep bowel cleansing agent
|
5/24/2006 | BT | Salix: Xifaxan shows improvement in more than 80% of pouchitis patients
|
5/23/2006 | BT | Salix says Osmoprep effective colonoscopy aid
|
5/22/2006 | BT | Salix says Xifaxan provides relief for irritable bowel syndrome; other drug data released
|
5/18/2006 | BT | Salix issued Xifaxan patent
|
5/4/2006 | BT | Market Commentary: Bausch & Lomb stock sinks after buyback offering to avoid default; ImmunoGen stock up on earnings
|
4/19/2006 | BT | Salix study finds OsmoPrep liquid bowel cleanser superior
|
4/11/2006 | BT | FDA issues approvable letter for MoviPrep, Salix-licensed colonoscopy bowel cleanser
|
3/17/2006 | BT | Market Commentary: Sunesis stock leaps 11.4% on $45 million PIPE; Salix's stock drops on FDA approval of OsmoPrep
|
3/17/2006 | BT | Salix: FDA gives marketing approval for OsmoPrep Tablets
|
2/24/2006 | BT | Salix Pharmaceuticals says 2005 revenues up 52% to $154.7 million
|
1/11/2006 | BT | Salix starts three late-stage trials of treatments for gastrointestinal disease
|
1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
1/4/2006 | BT | Salix says phase 3 trial shows Xifaxan successfully prevents travelers from getting diarrhea
|
12/7/2005 | BT | Salix still peer perform by Thomas Weisel
|
12/7/2005 | BT | Salix acquires Norgine's liquid bowel cleansing product to market in United States
|
11/1/2005 | BT | Salix: Colazal, INKP-102 advancing in trials
|
10/31/2005 | BT | Salix reports positive findings in six trials of Xifaxan
|
10/3/2005 | BT | Salix Pharmaceuticals merges with InKine Pharmaceutical
|
8/9/2005 | BT | Salix kept by Thomas Weisel at peer perform
|
7/7/2005 | BT | Market Commentary: Accentia delays IPO on positive news; Salix takes off; Millipore gains; Sepracor off; Amgen soars
|
6/23/2005 | BT | Market Commentary: Forest Labs up sharply; King sees buying; Avalon sets IPO range; Salix dives; Xoma, ViaCell bounce
|